Back to discover
Drug

Idecabtagene vicleucel

Approved · EMA
ClassTumor necrosis factor receptor superfamily member 17 binding agentEmerging researchLate-stage development

Also known as Abecma, Anti-BCMA CAR T cell, IDE-CEL.

RxNorm2536430ChEMBLCHEMBL4298199ATCL01XL07UNII8PX1X7UG4D
1
Research papers
2
Active clinical trials
TNFRSF17
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy Using Ide-Cel for Multiple Myeloma Patients Status Post Hematopoietic Cell Transplantation

Clinical trial2026-04-02Results expected Q2 2027 · ClinicalTrials.gov

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Clinical trial2025-08-11Primary completion · ClinicalTrials.gov

Approval: Abecma (EMA)

Regulatory2021-08-18EMA

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Research2021-02-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Idecabtagene vicleucel
Aliases & brands
AbecmaAnti-BCMA CAR T cellIDE-CEL
RxNorm CUI
2536430
ChEMBL ID
CHEMBL4298199
ATC codes
L01XL07
UNII
8PX1X7UG4D
Primary mechanism
Tumor necrosis factor receptor superfamily member 17 binding agent
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Tumor necrosis factor receptor superfamily member 17
TNFRSF17 · Q02223
BINDING AGENTTumor necrosis factor receptor superfamily member 17 binding agent

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2021-08-18
Latest approval
2021-08-18
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2021-08-18Approval
Approval: Abecma (EMA)
Indication: Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory… Show full indication

Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
2
registered trials across all phases
2
Active studies
1
Late-stage (III+)
PHASE DISTRIBUTIONn = 2
Phase 21Phase 31

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

The New England journal of medicine · 2021 · 1,903 cites
Recent papers

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

The New England journal of medicine · 2021 · 1,903 cites
Major research themes1
Immunotherapy, Adoptive1
Journals, researchers & institutions
Top journals
  • The New England journal of medicine1
Leading researchers
  • Anderson LD Jr1
  • Berdeja J1
  • Campbell TB1
  • Cavo M1
  • Connarn JN1
  • Delforge M1
  • Einsele H1
  • Goldschmidt H1
Leading institutions
free-text, unnormalised
  • From the Jerome Lipper Multiple Myeloma Center1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.